Health Technology Healios KK Business Summary
Healios KK engages in the research, development, and sale of cellular and regenerative medicine. It develops therapies for ischemic stroke, acute respiratory distress syndrome, liver disease, and age-regulated macular degeneration. The company was founded by Tadahisa Kagimoto on February 24, 2011 and is headquartered in Tokyo, Japan.
Financial Highlights
Dec 2019
JPY USD Revenue 0 0 Gross Profit -69M -0.63M Operating income -4,271M -39.17M Income before tax -4,403M -40.39M Net income -4,410M -40.45M EBITDA -4,202M -38.54M Diluted EPS -87.96 -0.80 Dividends Per Share 0 0 Total Assets 21,101M 194.16M Total liabilities 12,124M 111.56M Total equity 8,976M 82.59M Operating cash flow -4,970M -45.59M Currency in JPY Currency in USD
Historical Data Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Revenue
98.16M
77.64M
27.66M
0
0
Gross Profit
-74.69M
-100.81M
-75.96M
-78M
-69M
Operating income
-1,060.41M
-3,507.46M
-2,348.20M
-5,063M
-4,271M
Income before tax
-958.12M
-3,426.74M
-1,771.55M
-5,091M
-4,403M
Net income
-958.10M
-3,433.55M
-1,776.65M
-5,097M
-4,410M
EBITDA
-896.94M
-3,338.15M
-2,247.89M
-4,985M
-4,202M
Diluted EPS
-25.60
-84.33
-39.73
-103.51
-87.96
Dividends Per Share
0
0
0
0
0
Total Assets
10,487.61M
9,174.98M
19,696.42M
14,980M
21,101M
Total liabilities
1,110.25M
3,180.55M
3,532.74M
4,196M
12,124M
Total equity
9,377.36M
5,994.42M
16,163.67M
10,782M
8,976M
Operating cash flow
-167.17M
-3,782.67M
-1,762.18M
-5,148M
-4,970M
Dec 2015 Dec 2016 Dec 2017 Dec 2018 Dec 2019 Revenue
0.81M
0.71M
0.24M
0
0
Gross Profit
-0.61M
-0.92M
-0.67M
-0.70M
-0.63M
Operating income
-8.75M
-32.27M
-20.94M
-45.84M
-39.17M
Income before tax
-7.91M
-31.53M
-15.79M
-46.09M
-40.39M
Net income
-7.91M
-31.59M
-15.84M
-46.15M
-40.45M
EBITDA
-7.40M
-30.72M
-20.04M
-45.13M
-38.54M
Diluted EPS
-0.21
-0.77
-0.35
-0.93
-0.80
Dividends Per Share
0
0
0
0
0
Total Assets
87.18M
78.66M
174.84M
136.53M
194.16M
Total liabilities
9.22M
27.26M
31.36M
38.24M
111.56M
Total equity
77.95M
51.39M
143.48M
98.27M
82.59M
Operating cash flow
-1.38M
-34.81M
-15.71M
-46.61M
-45.59M
Valuation Measures
Dec 2019
PER -- ROA -24.44% ROE -44.64% Operating margin -- Profit margin --
Key executives
President, Chief Executive Officer & Director:
Tadahisa Kagimoto
Chief Financial Officer & Director:
Richard Patrick Kincaid
Chief Medical Officer & Executive Vice President:
Masanori Sawada
Executive Officer, Head-Research & Production Area:
Kouichi Tamura
Executive Officer & Head-Development Area:
Michihisa Nishiyama Shareholders
KAGIMOTO TADAHISA (55.1%)
JPMorgan Asset Management (Japan) Ltd. (3.9%)
Baillie Gifford & Co. (3.8%)
Asset Management One Co., Ltd. (3.8%)
Nikon Corp. (2.9%)
Sumitomo Dainippon Pharma Co., Ltd. (2.9%)
Nomura Asset Management Co., Ltd. (2.2%)
Matthews International Capital Management LLC (2.2%)
FUJIOKA YOSHIHISA (1.3%)
TAKEDA HIDEKI /HEALIOS/ (1.0%)
Related Companies
Healios N.A., Inc.
Sighregen Co., Ltd.
Competitors
Roche Holding AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Bayer AG
Santen Pharmaceutical Co., Ltd.
Pluristem Therapeutics Inc.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 23 Oct, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
